Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| NOVAVAX INCNVAX · Entity 4632 | President and COO | March 07, 2025 | March 11, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
NOVAVAX INC
Report date March 07, 2025 · Filed March 11, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 68,061 |
Ending reported balance
After 2025-03-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2025-03-07 · Exercise / conversion · Acquired 28,890 · Balance 82,015 Row 2 · 2025-03-07 · Tax withholding · Disposed 13,954 · Balance 68,061 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $0.00 · Expires 2033-03-07 | Direct | 28,890 |
Reported balance
After 2025-03-07 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2025-03-07 · Exercise / conversion · Disposed 28,890 · Balance 28,890 F1: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 07, 2025 Filed Mar 11, 2025 20:34 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 28,890 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000333 · primary_01.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,890 Underlying: Common Stock · 28,890 shares Expires 2033-03-07 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the March 7, 2023 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:34 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 13,954 | $8.34 | $116,376.36 |
DisclosureSEC source: 0001593968-25-000333 · primary_01.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 68,061 Read SEC document |
| March 07, 2025 Filed Mar 11, 2025 20:34 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 28,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000333 · primary_01.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 82,015 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 48,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000289 · primary_01.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,000 Underlying: Common Stock · 48,000 shares Expires 2034-03-01 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 23,185 | $8.33 | $193,131.05 |
DisclosureSEC source: 0001593968-25-000289 · primary_01.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 53,125 Read SEC document |
| March 01, 2025 Filed Mar 4, 2025 23:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 48,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-25-000289 · primary_01.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 76,310 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 655 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001090 · primary_01.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 655 shares Expires 2031-08-19 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan vest on each of the first three (3) anniversaries of the grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 317 | $13.90 | $4,406.30 |
DisclosureSEC source: 0001593968-24-001090 · primary_01.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,310 Read SEC document |
| August 19, 2024 Filed Aug 21, 2024 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 655 | $0.00 | $0.00 |
DisclosureSEC source: 0001593968-24-001090 · primary_01.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 28,627 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:45 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,608 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033619 · tm248710-1_4seq1.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 4,608 Underlying: Common Stock · 4,608 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of March 10, 2022, the Grant Date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of March 10, 2022, the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:45 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,226 | $5.45 | $12,131.70 |
DisclosureSEC source: 0001104659-24-033619 · tm248710-1_4seq1.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 27,972 Read SEC document |
| March 10, 2024 Filed Mar 13, 2024 00:45 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,608 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033619 · tm248710-1_4seq1.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · President and COO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,198 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 28,890 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-033164 · tm248549-2_4seq1.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 57,780 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of March 7, 2023, the Grant Date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Amended and Restated 2015 Stock Incentive Plan will vest on each of the first three (3) anniversaries of March 7, 2023, the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 13,955 | $5.61 | $78,287.55 |
DisclosureSEC source: 0001104659-24-033164 · tm248549-2_4seq1.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 25,590 Read SEC document |
| March 07, 2024 Filed Mar 12, 2024 01:40 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 28,890 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-24-033164 · tm248549-2_4seq1.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 39,545 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 01, 2024 Filed Mar 26, 2024 23:03 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 144,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001104659-24-039169 · tm249879-6_4seq1.xml · derivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 144,000 Underlying: Common Stock · 144,000 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F2 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the March 1, 2024 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-058990 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F1 · derivative.exercise_date: The restricted stock units ("RSU"s) subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. F1 · derivative.expiration_date: The restricted stock units ("RSU"s) subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 773 | $5.69 | $4,398.37 |
DisclosureSEC source: 0001209191-23-058990 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,655 F2 · kind: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. Read SEC document |
| December 14, 2023 Filed Dec 18, 2023 22:12 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-058990 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,428 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units ("RSU"s) subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 19, 2023 Filed Aug 22, 2023 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-046915 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 655 Underlying: Common Stock · 655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 19, 2021 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 19, 2021 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 19, 2023 Filed Aug 22, 2023 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 317 | $7.14 | $2,263.38 |
DisclosureSEC source: 0001209191-23-046915 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,828 Read SEC document |
| August 19, 2023 Filed Aug 22, 2023 20:47 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-046915 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 10,145 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 25, 2023 Filed Jun 27, 2023 20:32 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-039891 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment with the Company through such vesting date. Read SEC document |
| June 25, 2023 Filed Jun 27, 2023 20:32 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 403 | $6.70 | $2,700.10 |
DisclosureSEC source: 0001209191-23-039891 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,490 Read SEC document |
| June 25, 2023 Filed Jun 27, 2023 20:32 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-23-039891 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,893 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 4,609 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-018553 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,216 Underlying: Common Stock · 4,609 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F3 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the March 10, 2022 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 2,471 | $6.52 | $16,110.92 |
DisclosureSEC source: 0001209191-23-018553 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,060 Read SEC document |
| March 10, 2023 Filed Mar 14, 2023 21:20 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 4,609 | $6.52 | $30,050.68 |
DisclosureSEC source: 0001209191-23-018553 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,531 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the reporting person in connection with vesting of restricted stock units ("RSUs"). Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 86,670 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-23-017586 · doc4.xml · derivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 86,670 Underlying: Common Stock · 86,670 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 07, 2023 Filed Mar 9, 2023 22:02 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 100,100 | $0.00 Strike: $6.97 | $0.00 |
DisclosureSEC source: 0001209191-23-017586 · doc4.xml · derivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,100 Underlying: Common Stock · 100,100 shares Expires 2033-03-07 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 7, 2023 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-061707 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,600 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F5 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. F5 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 773 | $17.23 | $13,318.79 |
DisclosureSEC source: 0001209191-22-061707 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,922 F3 · kind: The shares were withheld by the Company to satisfy tax withholding obligations in connection with the vesting of RSUs. F4 · balance_after: The shares reported on this Form 4 are subject to a lock-up agreement between the Reporting Person, J.P. Morgan Securities LLC and Jefferies LLC, dated December 14, 2022. Read SEC document |
| December 14, 2022 Filed Dec 16, 2022 22:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-061707 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,695 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The shares were received by the Reporting Person in connection with vesting of restricted stock units ("RSUs"). F2 · price: Each RSU represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 3,538 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-051474 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 3,538 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the September 26, 2019 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 1,709 | $18.87 | $32,248.83 |
DisclosureSEC source: 0001209191-22-051474 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,095 Read SEC document |
| September 26, 2022 Filed Sep 28, 2022 21:04 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 3,538 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-051474 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,804 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 655 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-047212 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,310 Underlying: Common Stock · 655 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 19, 2021 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the August 19, 2021 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 317 | $36.22 | $11,481.74 |
DisclosureSEC source: 0001209191-22-047212 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,266 Read SEC document |
| August 19, 2022 Filed Aug 23, 2022 21:03 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 655 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-047212 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,583 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 833 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-039639 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 833 Underlying: Common Stock · 833 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the June 25, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 278 | $51.67 | $14,364.26 |
DisclosureSEC source: 0001209191-22-039639 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,928 Read SEC document |
| June 25, 2022 Filed Jun 28, 2022 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 833 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-22-039639 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,206 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantRestricted Stock Units · Derivative | 13,825 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-018660 · doc4.xml · derivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,825 Underlying: Common Stock · 13,825 shares Expires not disclosed F2 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Company's common stock. F3 · derivative.exercise_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. F3 · derivative.expiration_date: One-third (1/3) of the RSUs subject to this grant under the Plan will vest on each of the first three (3) anniversaries of the Grant Date, in each case subject to continued employment through such vesting date. Read SEC document |
| March 10, 2022 Filed Mar 14, 2022 23:51 UTC | NOVAVAX INC NVAX · Entity 4632 | GrantStock Option (Right to Buy) · Derivative | 20,737 | $0.00 Strike: $77.77 | $0.00 |
DisclosureSEC source: 0001209191-22-018660 · doc4.xml · derivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,737 Underlying: Common Stock · 20,737 shares Expires 2032-03-10 F1 · derivative.exercise_date: Twenty-five percent (25%) of the shares subject to this option grant under the Novavax, Inc. (the "Company") Amended and Restated 2015 Stock Incentive Plan, as amended (the "Plan"), will vest on the first anniversary of the March 10, 2022 grant date (the "Grant Date"), and the remaining seventy-five percent (75%) of the shares will vest in equal monthly installments over the following three (3) years, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:18 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionRestricted Stock Units · Derivative | 1,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-21-070021 · doc4.xml · derivative · entry 3 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,200 Underlying: Common Stock · 1,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. F2 · derivative.exercise_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. F2 · derivative.expiration_date: The RSUs subject to this grant under the Company's Amended and Restated 2015 Stock Incentive Plan, as amended, vested or will vest with respect to one-third (1/3) of the RSUs on each of the first three (3) anniversaries of the December 14, 2020 grant date, in each case subject to continued employment through such vesting date. Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:18 UTC | NOVAVAX INC NVAX · Entity 4632 | Tax withholdingCommon Stock | 773 | $168.43 | $130,196.39 |
DisclosureSEC source: 0001209191-21-070021 · doc4.xml · nonDerivative · entry 2 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,373 Read SEC document |
| December 14, 2021 Filed Dec 16, 2021 22:18 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionCommon Stock | 1,600 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-21-070021 · doc4.xml · nonDerivative · entry 1 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,146 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Novavax, Inc. (the "Company") common stock. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | Exercise / conversionStock Option (Right to Buy) · Derivative | 7,501 | $0.00 Strike: $19.08 | $0.00 |
DisclosureSEC source: 0001209191-21-058075 · doc4.xml · derivative · entry 20 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,000 Underlying: Common Stock · 7,501 shares Expires 2030-04-17 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F18 · derivative.exercise_date: On April 17, 2020, the reporting person was granted an option to purchase 140,000 shares of common stock of Novavax, Inc. (the "Company") pursuant to the Company's Amended and Restated 2015 Stock Incentive Plan, as amended. The vesting of the shares subject to this option grant is subject to the satisfaction of a performance-based vesting requirement, followed by time-based vesting. The performance metric required that the Company initiate a COVID-19 Phase 2 clinical trial within twelve (12) months of the grant date, which occurred when the Company initiated its Phase 2 clinical trial of NVX-CoV2373 in the U.S. on August 24, 2020. Following that event, fifty percent (50%) of the shares vested on August 24, 2021, the first anniversary of the initiation date, and the remaining fifty percent (50%) of the shares will vest on August 24, 2022, the second anniversary of the initiation date subject to continued employment through such vesting date. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 156 | $230.00 | $35,879.64 |
DisclosureSEC source: 0001209191-21-058075 · doc4.xml · nonDerivative · entry 19 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,546 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F17 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $229.94 to $230.03, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
| September 28, 2021 Filed Sep 29, 2021 21:06 UTC | NOVAVAX INC NVAX · Entity 4632 | SaleCommon Stock | 323 | $228.25 | $73,725.30 |
DisclosureSEC source: 0001209191-21-058075 · doc4.xml · nonDerivative · entry 18 Trizzino John · CIK 0001468534 · EVP, CCO and CBO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,702 F1 · kind: The transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person. F16 · price: The reported price is a weighted average price. These shares were sold in multiple transactions at prices ranging from $228.19 to $228.42, inclusive. The reporting person undertakes to provide to Novavax, Inc., any security holder of Novavax, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each price within the range set forth in this footnote. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.